BioMarin Pharmaceutical Inc
SWB:BM8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioMarin Pharmaceutical Inc
SWB:BM8
|
US |
|
Origin Energy Ltd
ASX:ORG
|
AU |
|
A
|
AceBed
KOSDAQ:003800
|
KR |
|
Softronic AB
STO:SOF B
|
SE |
|
Landis+Gyr Group AG
SIX:LAND
|
CH |
|
L
|
Lucara Diamond Corp
SWB:LKT
|
CA |
|
Ability Inc
OTC:ABILF
|
IL |
|
Packaging Corp of America
NYSE:PKG
|
US |
|
General de Alquiler de Maquinaria SA
MAD:GAM
|
ES |
|
Kofola CeskoSlovensko as
LSE:0RD3
|
CZ |
|
C
|
Chesterfield Special Cylinders Holdings PLC
F:PRS
|
UK |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BM8's stock price target?
Price Target
78.69
EUR
According to Wall Street analysts, the average 1-year price target for 
BM8 is 78.69 EUR with a low forecast of 51.95 EUR and a high forecast of 111.61 EUR.
What is the Revenue forecast for BioMarin Pharmaceutical Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for BioMarin Pharmaceutical Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 8 years is 8%.
What is the Operating Income forecast for BioMarin Pharmaceutical Inc?
Projected CAGR
14%
The compound annual growth rate for Operating Income over the next 8 years is 14%.
What is the Pre-Tax Income forecast for BioMarin Pharmaceutical Inc?
Projected CAGR
48%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 48%.
What is the Net Income forecast for BioMarin Pharmaceutical Inc?
Projected CAGR
24%
The compound annual growth rate for Net Income over the next 8 years is 24%.